Lipid and glucose abnormalities and associated factors among children living with HIV in Asia [0.03%]
亚洲HIV感染儿童的血脂和血糖异常及其相关因素分析
Tulathip Suwanlerk,Dhanushi Rupasinghe,Watsamon Jantarabenjakul et al.
Tulathip Suwanlerk et al.
Background: Children living with HIV (CLHIV) on prolonged antiretroviral therapy (ART) are at risk for lipid and glucose abnormalities. Prevalence and associated factors were assessed in a multicentre, Asian longitudinal ...
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts [0.03%]
南非观察队列中婴儿HIV患者使用阿巴卡韦的安全性及有效性研究
Reneé de Waal,Helena Rabie,Karl-Günter Technau et al.
Reneé de Waal et al.
Background: WHO guidelines recommend abacavir in first-line antiretroviral treatment for children and neonates. However, there is no approved dose
Observational Study
Antiviral therapy. 2023 Feb;28(2):13596535231168480. DOI:10.1177/13596535231168480 2023
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting [0.03%]
治疗相关的早期停药和不良事件——在真实世界中启动整合酶抑制剂初治HIV感染者的特征分析
Charlotte-Paige Rolle,Jamie Castano,Vu Nguyen et al.
Charlotte-Paige Rolle et al.
Background: Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were consider...
Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation [0.03%]
个例报告及文献复习：一例呃逆合并脑炎和十二指肠穿孔患者
Fanfeng Kong,Xiao Xue Zeng
Fanfeng Kong
Brainstem encephalitis is rare and this study aims to report the clinical course, imaging features, and therapeutic response of hiccup patient with gastric ulcer who developed brainstem encephalitis with Epstein-Barr virus (EBV) detected in...
Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review [0.03%]
Biktarvy治疗 HIV-1 感染的疗效、安全性和耐受性：系统评价
Ellen Peters,And Collins Iwuji
Ellen Peters
Background: Biktarvy is approved for use in HIV-1 infection in both treatment-naïve and treatment-experienced individuals, after a series of successful phase III trials. However, studies on real-world evidence on its efficacy, safety and t...
Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ [0.03%]
N-ω-Chloroacetyl-L-Ornithine抑制登革病毒复制作用及其机制研究
Lucero Rojas-Luna,Araceli Posadas-Modragón,Amanda M Avila-Trejo et al.
Lucero Rojas-Luna et al.
Background: Polyamines are involved in several cellular processes and inhibiting their synthesis affects chikungunya virus (CHIKV) replication and translation, and, therefore, reduces the quantity of infectious viral part...
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants [0.03%]
健康成人参与者中TLR7激动剂JNJ-64794964的群体药代动力学/药效学模型
Liviawati S Wu,Yue Hu,Edward J Gane et al.
Liviawati S Wu et al.
Background: JNJ-4964 is a TLR7 agonist, which, via a type I interferon (IFN)-dependent mechanism, may enhance host immunity suppressed by persistent exposure to hepatitis B antigens in chronic hepatitis B. ...
Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration [0.03%]
正在接受连续性静脉-静脉血液滤过治疗的危重患者的扎那米韦药代动力学特征研究
André Wieringa,Peter Gj Ter Horst,GertJan Hj Wagenvoort et al.
André Wieringa et al.
Background: Limited data exist for dosing of zanamivir in the setting of CVVH in the intensive care unit (ICU). Our objective is to report the pharmacokinetics and sieving coefficient (Sv) of zanamivir in patients receivi...
Observational Study
Antiviral therapy. 2023 Feb;28(1):13596535221150746. DOI:10.1177/13596535221150746 2023
A favipiravir-induced angioedema and urticaria in a COVID-19 patient [0.03%]
COVID-19患者中由法维拉韦引起的血管性水肿和荨麻疹
Figen Ergur Ozturk,Ayperi Ozturk,Hale Ates
Figen Ergur Ozturk
Although favipiravir is a promising drug for coronavirus disease 2019, some adverse effects, including skin lesions, have been reported. A 56-year-old female who was prescribed favipiravir by a filiation team following a positive severe acu...
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C [0.03%]
直接抗病毒治疗对慢性丙型肝炎患者体重的影响的理解
Chinyere L Nkwocha,Pamela S Carter,Somer Blair et al.
Chinyere L Nkwocha et al.
Background: Direct-acting antivirals (DAAs) have revolutionized treatment for HCV. Compared to interferon-based therapies, DAAs achieve higher rates of sustained virologic response, with more tolerable side effects. Nonet...